Radiation Oncology The radiation oncology multidisciplinary team is actively involved in cancer research and looks to improve patient outcomes through sophisticated radiotherapy. Translational research is a core focus of the group, and initiatives that were previously part of research projects conducted at NSLHD have been incorporated into standard care for patients. We strive to be patient-centric focus on individualised treatment pathways which is reflected in publications and research themes, and radiation oncology has strong collaborations with medical oncology, surgical oncology, allied health and nursing across NSLHD. Clinical trials are an important component of the radiation oncology research portfolio, and the group steers multiple phase I and II clinical trials for innovative treatment; for brain cancer, pancreas cancer and prostate cancer. This enables our patients to be involved in potentially life-saving treatment and access to treatments they may otherwise not have had. Our patients benefit directly through our research and involvement with clinical trials.
A key example of how radiation oncology research leads to better patient outcomes was the development of a streamlined palliative care pathway which removed the need for a simulation computed tomography (sCT) scan, meaning more prompt treatment delivery and fewer attendances for the patient. The radiotherapy unit is a collaborative research partner with Varian Medical Systems, participating an international consortium for adaptive radiotherapy and leading development for risk assessment, adaptive cervix radiotherapy, adaptive rectal cancer radiotherapy and simulation-free palliative radiotherapy. The district’s radiotherapy unit is a reference site for US-based radiation dosimetry software company, Sun Nuclear Corporation, and for Canadian-based 3D printing software company Adaptiiv. We have strong links with the University of Sydney, as a teaching and research partner.
Publications: › Back M, Jayamanne D, Brazier D, Newey A, Bailey D, Schembri G, Hsiao E, Khasraw M, Wong M, Kastelan M, Brown C, Wheeler H. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. Strahlenther Onkol . 2020 Jan;196(1):31-39. English. doi: 10.1007/s00066-019-01467-0. Epub 2019 Apr 26. PMID: 31028406 › Booth J, Caillet V, Briggs A, et al. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose. Radiother Oncol . Feb 2021;155:131-137. doi:10.1016/j. radonc.2020.10.036 › Horsley PJ, Back M, Lamoury G, Porter B, Booth J, Eade TN. Radiation oncology during COVID-19: Strategies to avoid compromised care. Asia Pac J Clin Oncol. Feb 2021;17(1):24-28. doi:10.1111/ajco.13456 › Itchins M, Chua TC, Arena J, et al. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Pancreas. Feb 2020;49(2):224-229. doi:10.1097/mpa.0000000000001472 › Oar A, Lee M, Le H, et al. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol . May-Jun 2020;10(3):e136-e146. doi:10.1016/j.prro.2019.07.018
24
RESEARCH ANNUAL REPORT 2020
Made with FlippingBook - professional solution for displaying marketing and sales documents online